We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+6.27%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.02B
AUM Growth
-$45.6M
Cap. Flow
-$64.3M
Cap. Flow %
-6.32%
Top 10 Hldgs %
45.69%
Holding
126
New
39
Increased
20
Reduced
28
Closed
30

Top Buys

Rank Stock Value
1
BTAI icon
BioXcel Therapeutics
BTAI
+$12.6M
2
JNJ icon
Johnson & Johnson
JNJ
+$11.8M
3
GNRC icon
Generac Holdings
GNRC
+$11M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$10.6M
5
LLY icon
Eli Lilly
LLY
+$10.2M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$41.2M
2
NVO
Novo Nordisk
NVO
+$26.2M
3
NICE icon
Nice
NICE
+$14.2M
4
FVRR icon
Fiverr
FVRR
+$11.8M
5
QTTB icon
Q32 Bio
QTTB
+$10M

Sector Composition

Rank Sector Weight
1 Healthcare 70.42%
2 Technology 5.67%
3 Consumer Discretionary 2.57%
4 Industrials 2.19%
5 Communication Services 1.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRK icon
1
Merck
MRK
$322B
$73.3M 7.2%
926,231
+104,800
+13% +$8.21M
ABBV icon
2
AbbVie
ABBV
$443B
$69.2M 6.8%
790,000
+55,402
+8% +$5.22M
QQQ icon
3
PUT
Invesco QQQ Trust
QQQ
$453B
$58.3M 5.73%
210,000
+52,500
+33% +$14.2M
JNJ icon
4
Johnson & Johnson
JNJ
$618B
$56.6M 5.56%
380,000
+80,000
+27% +$11.8M
SNY icon
5
Sanofi
SNY
$103B
$56.2M 5.52%
1,120,000
– –
AZN icon
6
AstraZeneca
AZN
$263B
$44.9M 4.42%
410,000
-35,000
-8% -$3.89M
LLY icon
7
CALL
Eli Lilly
LLY
$1.02T
$29.6M 2.91%
+200,000
New +$31M
AMGN icon
8
Amgen
AMGN
$208B
$28M 2.75%
110,000
+30,000
+38% +$7.43M
NVS icon
9
Novartis
NVS
$297B
$24.8M 2.44%
285,000
+105,000
+58% +$9.1M
SRPT icon
10
Sarepta Therapeutics
SRPT
$1.57B
$24.1M 2.37%
171,500
+48,300
+39% +$7.34M
LLY icon
11
Eli Lilly
LLY
$1.02T
$23.1M 2.27%
156,000
+66,000
+73% +$10.2M
SRPT icon
12
CALL
Sarepta Therapeutics
SRPT
$1.57B
$21.1M 2.07%
+150,000
New +$22.8M
SRPT icon
13
PUT
Sarepta Therapeutics
SRPT
$1.57B
$21.1M 2.07%
+150,000
New +$22.8M
DCPH
14
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$17.6M 1.73%
343,965
+61,000
+22% +$2.99M
FOLD
15
DELISTED
Amicus Therapeutics
FOLD
$17.6M 1.73%
1,243,550
-385,000
-24% -$5.61M
YMAB
16
DELISTED
Y-mAbs Therapeutics
YMAB
$15.2M 1.5%
396,521
+114,269
+40% +$4.55M
TEVA icon
17
Teva Pharmaceuticals
TEVA
$40.8B
$14.3M 1.4%
1,582,878
+1,000,000
+172% +$10.6M
NICE icon
18
Nice
NICE
$5.79B
$14.2M 1.39%
62,481
-66,925
-52% -$14.2M
GNRC icon
19
Generac Holdings
GNRC
$11.6B
$13M 1.27%
+67,000
New +$11M
IWP icon
20
PUT
iShares Russell Mid-Cap Growth ETF
IWP
$19.8B
$12.7M 1.25%
+147,000
New +$12.4M
AMZN icon
21
Amazon
AMZN
$2.92T
$12M 1.18%
76,400
-10,000
-12% -$1.58M
BTAI icon
22
BioXcel Therapeutics
BTAI
$24.9M
$11.7M 1.15%
+16,831
New +$12.6M
MYOK
23
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$11M 1.09%
81,000
-19,000
-19% -$2.02M
KURA icon
24
Kura Oncology
KURA
$800M
$11M 1.08%
359,494
-175,000
-33% -$3.86M
ABBV icon
25
CALL
AbbVie
ABBV
$443B
$10.9M 1.08%
+125,000
New +$11.8M
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2020 Portfolio in Review

As of Q3 2020, Sphera Funds Management held 126 positions worth $1.02B, down 4.3% from $1.06B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Sphera Funds Management withdrew a net $64.3M in Q3 2020, closing 30 positions and reducing 28 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $41.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 64% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Sphera Funds Management opened a new position in BioXcel Therapeutics worth $11.7M.

  • Sphera Funds Management's largest Q3 2020 buy was BioXcel Therapeutics: 16,831 shares worth $11.7M.
  • Sphera Funds Management added most to Johnson & Johnson in Q3 2020, an estimated $11.8M increase.
  • Sphera Funds Management's biggest Q3 2020 reduction was Nice, cutting an estimated $14.2M.
  • Sphera Funds Management fully exited Bristol-Myers Squibb in Q3 2020, selling an estimated $41.2M.
  • Sphera Funds Management's ten largest holdings make up 46% of its $1.02B portfolio in Q3 2020.
  • Sphera Funds Management opened 39 new positions and closed 30 in Q3 2020.
  • Sphera Funds Management's portfolio value fell 4.3% quarter-over-quarter to $1.02B.

Based on Sphera Funds Management's 13F filing for Q3 2020, filed 12 Nov 2020.